Tri-sprintec

   
Google
 
Web NewDrugInformation.com

Tri-sprintec


Drug - Tri-sprintec
The trade name of the product as shown on the labeling.

Dosage - TABLET; ORAL-28
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Ethinyl Estradiol; Norgestimate
Multiple ingredients are in alphabetical order.

Strength - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG
The potency of the active ingredient(s), Ethinyl Estradiol; Norgestimate. May repeat for multiple part products.

Applicant - BARR
The firm name holding legal responsibility for Tri-sprintec. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 075808
The FDA assigned number to Tri-sprintec. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Tri-sprintec. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Dec 29, 2003
The date Tri-sprintec was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Tri-sprintec. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Tri-sprintec is in. Format is RX, OTC, DISCN.

Applicant Full Name - Barr Laboratories Inc
The full name of the firm holding legal responsibility for the new application of Tri-sprintec.

Tri-sprintec